A high risk of arrhythmias was reported in myotonic dystrophy (MD). The purpose of the study was to evaluate the value of non-invasive and invasive investigations for the arrhythmias detection and when to repeat the investigations. 129 patients, mean age 41 ± 14 years, with MD, were asymptomatic, except 4. Electrocardiogram (ECG), left ventricular ejection fraction determination, Holter monitoring, signal-averaged ECG, electrophysiological study (51) were obtained and repeated each year in patients without conduction abnormalities. Electrocardiogram and Holter monitoring were normal in 72 and 89 patients, respectively. Standard deviation of the mean RR intervals (SDNN) was <100 ms in 30 patients. Late potentials were present in 32 patients, without ventricular tachycardia (VT) correlation. Ejection fraction was normal in all but six patients (60±10.5%). HV interval was prolonged in 0 of 8 patients with normal ECG, 1 of 9 with isolated first degree atrioventricular block, 9 of 16 with hemiblock, and 10 of 15 with bundle branch block. Atrial fibrillation (AF) was induced in 22 patients, non-sustained VT in 6 patients, and sick sinus syndrome noted in 10 patients. The mean time for the ECG change was 5±1 years. After 10±7.5 years, AF occurred in 15 patients; 12 patients died. Multivariate analysis indicated that both AF at ECG and SDNN lower than 100 ms were independent predictors of death. HV increase was noted only in patients with abnormal ECG. The most frequent arrhythmia was AF and was associated with a high risk of death. The repetition of ECG every year is probably not useful.

Download full-text PDF

Source
http://dx.doi.org/10.1093/europace/euq423DOI Listing

Publication Analysis

Top Keywords

myotonic dystrophy
8
holter monitoring
8
long-term follow-up
4
patients
4
follow-up patients
4
patients myotonic
4
dystrophy electrocardiogram
4
electrocardiogram year
4
year high
4
high risk
4

Similar Publications

Evaluation of professional practices in the use of mexiletine for the management of childhood myotonia in French pediatric neuromuscular centers (MEXI-PEDI survey).

Arch Pediatr

January 2025

CMR Neuromusculaire, Service de génétique médicale, Hôpital Estaing, CHU de Clermont-Ferrand, Clermont-Ferrand, France. Electronic address:

Background: Myotonia is the main feature of both myotonic dystrophy (DM) and non-dystrophic myotonia (NDM). It is felt as stiffness, pain, fatigue, and weakness. In France, mexiletine, a non-selective voltage-gated sodium channel blocker, is approved for the treatment of myotonia in adults with NDM, and it has a temporary recommendation for use in the symptomatic treatment of DM in adults.

View Article and Find Full Text PDF

Atrial Fibrillation and Flutter in a Contemporary Cohort of Patients With Myotonic Muscular Dystrophy.

JACC Clin Electrophysiol

January 2025

Section of Cardiac Electrophysiology, Cardiovascular Medicine Division, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA.

Background: Literature on the prevalence and management of atrial arrhythmias in patients with myotonic muscular dystrophy type 1 (MMD1) or myotonic muscular dystrophy type 2 (MMD2) is limited.

Objectives: This study sought to describe incidence, prevalence, and predictors of atrial fibrillation (AF) and atrial flutter (AFL) in a contemporary cohort of patients with myotonic muscular dystrophy (MMD).

Methods: Associations between patient factors and incident AF/AFL were analyzed in patients with MMD referred for routine electrophysiology evaluation between January 2013 and September 2023.

View Article and Find Full Text PDF

Background: Myotonic dystrophy type 1 (DM1) is a multisystemic, CTG repeat expansion disorder characterized by a slow, progressive decline in skeletal muscle function. A biomarker correlating RNA mis-splicing, the core pathogenic disease mechanism, and muscle performance is crucial for assessing response to disease-modifying interventions. We evaluated the Myotonic Dystrophy Splice Index (SI), a composite RNA splicing biomarker incorporating 22 disease-specific events, as a potential biomarker of DM1 muscle weakness.

View Article and Find Full Text PDF

Background: We developed the FORCE platform to overcome limitations of oligonucleotide delivery to muscle and enable their applicability to neuromuscular disorders. The platform consists of an antigen-binding fragment, highly specific for the human transferrin receptor 1 (TfR1), conjugated to an oligonucleotide via a cleavable valine-citrulline linker. Myotonic dystrophy type 1 (DM1) is a neuromuscular disorder caused by expanded CUG triplets in the DMPK RNA, which sequester splicing proteins in the nucleus, lead to spliceopathy, and drive disease progression.

View Article and Find Full Text PDF

Sarcopenia, the pathological age-related loss of muscle mass and strength, contributes to physical decline, frailty, and diminished healthspan. The impact of sarcopenia is expected to rise as the aging population grows, and treatments remain limited. Therefore, novel approaches for enhancing physical function and strength in older adults are desperately needed.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!